Pharmaceuticals
Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome
CASTRES, France, April 26, 2024 /PRNewswire/ -- Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSA™ (vibegron under the international non-propriet...
2024-04-26 23:46
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers
* The second DMC review recommends the continuation of dose escalation in the clinical trial as per protocol. * The interim safety assessment was based on the review of safety data from 18 metastatic gastrointestinal cancer patients, including patients that have tolerated multiple doses of ca...
2024-04-26 21:00
518
Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa
SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year onApril 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger...
2024-04-26 12:39
719
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
SHANGHAI, April 25, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented in an ...
2024-04-25 22:00
714
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
* Oral session：ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for cervical cancer * Three Poster presentations: Phase I/II studies for ATG-031 (anti-CD24 monoclonal antibody) and ATG-022 (Claudin 18.2 antibody-drug conjugate) and selinexor(XPO1 Inhibitor) SHANGHA...
2024-04-25 20:00
1059
Onconic Therapeutics Receives MFDS Approval for JAQBO, a New Treatment for Gastroesophageal Reflux Disease (GERD)
SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD)...
2024-04-25 19:57
1020
Bazi Bushen Capsule Became the Representative Drug of Anti-aging Chinese Medicine
SHIJIAZHUANG, China, April 25, 2024 /PRNewswire/ -- On April 21, the 3rd Traditional Chinese Medicine Anti-Aging Conference, hosted by the World Federation of Chinese Medicine Societies, was held inShijiazhuang. Yiling Pharmaceutical'sBazi Bushen capsule, as a representative drug of anti-aging i...
2024-04-25 16:07
924
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic three-dimensional structures of alpha-helix and beta-turns of peptidesfor drug discoveryagainst oncology target selected by Ono TOKYO, April 25, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery ...
2024-04-25 14:00
645
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China, April 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2024-04-25 10:02
1096
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
SUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the co...
2024-04-25 09:02
887
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference. SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new med...
2024-04-24 22:10
1013
Future Health highlights greater access to treatment for Mental Health Month
SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- A recent poll
2024-04-24 22:00
772
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved inEurope Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /PR...
2024-04-24 15:00
1560
Samsung Biologics Reports First Quarter 2024 Financial Results
* Recorded Q1'24 consolidated revenue of KRW 946.9 billion * Recorded Q1'24 consolidated operating profit of KRW 221.3 billion * Sustained growth driven by ongoing strategic expansion in capacity and portfolio INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 20794...
2024-04-24 14:45
929
RELIFE BY A. MENARINI CHAMPIONS PERSONAL CHOICE IN AESTHETIC TREATMENTS, ENCOURAGING SELF-CARE AND SELF-LOVE
- The choice is the individual's hand to treat oneself with love and care, where judgments and negative opinions have no place in personal beauty journeys. KUALA LUMPUR, Malaysia, April 24, 2024 /PRNewswire/ -- RELIFE, the dermatology and aesthetic medicine division of A. Menarini, a wholl...
2024-04-24 10:00
1182
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO:Jae...
2024-04-24 09:27
853
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical ...
2024-04-23 18:37
1177
HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the N...
2024-04-23 14:54
919
Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing
SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately$20 million. This Pre-A round is led by Shunxi F...
2024-04-23 08:00
890
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
* Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024 DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therap...
2024-04-23 07:25
1372
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
9198
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
7771
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
5194
